In comparing all 409 cancer-related genes, KRAS (62.5% vs. 12.5% in Stage IIIA vs. Stage I) and TP53 (85.7% vs. 50%) trended to a higher mutation frequency in Stage IIIA compared to Stage I cancers, although this did not reach statistical significance (Table 2). Here, KRAS is linked to cancer.